World's First Lung Cancer Vaccine Trial Begins

A pioneering clinical trial for the world's first lung cancer preventative vaccine, LungVax, is scheduled to begin in summer 2026. Funded by Cancer Research UK, this four-year study will assess the vaccine's safety and optimal dosage in individuals at high risk of the disease. The vaccine utilizes mRNA technology, similar to COVID-19 vaccines, to train the immune system to recognize and eliminate abnormal lung cells by targeting specific proteins.

The trial will initially enroll patients who have successfully undergone treatment for early-stage lung cancer and are thus at high risk of recurrence, as well as those participating in the NHS Lung Cancer Screening Programme. Experts emphasize that while preventative vaccines offer a promising new avenue, they will not replace smoking cessation as the primary method for reducing lung cancer risk.

Lung cancer remains the most common and deadliest cancer worldwide. This initiative aims to shift the focus towards prevention, targeting the earliest stages of the disease. If successful, the vaccine could be offered to a broader population, potentially saving lives and reducing the significant burden of lung cancer, which causes tens of thousands of deaths annually in the UK alone.